Heckel America Email Formats

About Heckel America

Heckel America is revolutionizing cancer treatment with breakthrough water-filtered infrared hyperthermia technology. Our non-contact thermal system represents a quantum leap over traditional approaches, delivering precise, comfortable treatment that penetrates up to 3cm beneath the skin while eliminating the risk of burns. Our clinical results are compelling: In a landmark 2020 retrospective study of 170 patients with locally recurrent breast cancer (LRBC), 95% showed significant tumor response - with 43% achieving complete disappearance of detectable disease and 52% experiencing major tumor reduction. Unlike conventional microwave hyperthermia, limited to small tumors, our technology effectively treats large-scale tumors without field artifacts. We're preparing to launch our first U.S. clinical trial at the University of Maryland Medical Center, chosen for its extensive experience with hyperthermia treatments. UMMC recognizes the limitations of current microwave approaches - including patient discomfort and treatment constraints for larger tumors - making them an ideal partner for advancing this next-generation technology. In Europe, our technology is emerging as a game-changing solution for skin cancer patients, particularly elderly individuals, combining hyperthermia with just five low-dose radiation treatments as an alternative to disfiguring surgery. Now the standard of care for unresectable LRBC in the Swiss healthcare system, our technology is implemented across five public hospitals. Through partnerships with leading institutions including the University of Freiburg and King's College London, plus collaboration with heckel medizintechnik GmbH, we're advancing hyperthermia applications and exploring synergistic benefits with immunotherapy and chemotherapy.

View contact profiles from Heckel America